ADMA and the role of the genes: Lessons from genetically modified animals and human gene polymorphisms

Pharmacological Research

Volumn 60, Issue 6, 2009, Pages 475-480

  Maas, Renke ^a   Böger, Rainer ^b   Lüneburg, Nicole ^b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

DDAH; Dimethylarginine dimethylaminohydrolase; Knock out; Nitric oxide synthase; NOS; Overexpression; SNP

Indexed keywords

APOLIPOPROTEIN E; DIMETHYLARGININASE; DIMETHYLARGININASE 1; DIMETHYLARGININASE 2; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GUANYLATE CYCLASE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE; UNCLASSIFIED DRUG;

BRAIN HEMORRHAGE; ENDOTHELIAL DYSFUNCTION; GASTROINTESTINAL MOTILITY DISORDER; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEART INFARCTION; HUMAN; HYPERTENSION; LUNG RESISTANCE; NEPHROGENIC DIABETES INSIPIDUS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSGENIC ANIMAL; VASCULAR FIBROSIS;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ARGININE; DISEASE MODELS, ANIMAL; HUMANS; POLYMORPHISM, GENETIC;

EID: 70350044686     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2009.07.012     Document Type: Review

References (49)

1. Boger R.H., Sullivan L.M., Schwedhelm E., Wang T.J., Maas R., Benjamin E.J., et al. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 119 (2009) 1592-1600
2. Schnabel R., Blankenberg S., Lubos E., Lackner K.J., Rupprecht H.J., Espinola-Klein C., et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the atherogene study. Circ Res 97 (2005) e53-59
3. Zoccali C., Bode-Boger S., Mallamaci F., Benedetto F., Tripepi G., Malatino L., et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358 (2001) 2113-2117
4. Leiper J.M., Santa Maria J., Chubb A., MacAllister R.J., Charles I.G., Whitley G.S., et al. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J 343 Pt 1 (1999) 209-214
5. Dayoub H., Achan V., Adimoolam S., Jacobi J., Stuehlinger M.C., Wang B.Y., et al. Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence. Circulation 108 (2003) 3042-3047
6. Leiper J., Nandi M., Torondel B., Murray-Rust J., Malaki M., O'Hara B., et al. Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med 13 (2007) 198-203
7. Hasegawa K., Wakino S., Tatematsu S., Yoshioka K., Homma K., Sugano N., et al. Role of asymmetric dimethylarginine in vascular injury in transgenic mice overexpressing dimethylarginine dimethylaminohydrolase 2. Circ Res 101 (2007) e2-10
8. Nakata S., Tsutsui M., Shimokawa H., Suda O., Morishita T., Shibata K., et al. Spontaneous myocardial infarction in mice lacking all nitric oxide synthase isoforms. Circulation 117 (2008) 2211-2223
9. Friebe A., Mergia E., Dangel O., Lange A., and Koesling D. Fatal gastrointestinal obstruction and hypertension in mice lacking nitric oxide-sensitive guanylyl cyclase. Proc Natl Acad Sci USA 104 (2007) 7699-7704
10. Kielstein J.T., Impraim B., Simmel S., Bode-Boger S.M., Tsikas D., Frolich J.C., et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 109 (2004) 172-177
11. Achan V. Cardiovascular effects of asymmetric dimethylarginine. Circulation 109 (2004) e327 author reply e327
12. Xiao H.B., Yang Z.C., Jia S.J., Li N.S., Jiang D.J., Zhang X.H., et al. Effect of asymmetric dimethylarginine on atherogenesis and erythrocyte deformability in apolipoprotein e deficient mice. Life Sci 81 (2007) 1-7
13. Kielstein J.T., Simmel S., Bode-Boger S.M., Roth H.J., Schmidt-Gayk H., Haller H., et al. Subpressor dose asymmetric dimethylarginine modulates renal function in humans through nitric oxide synthase inhibition. Kidney Blood Press Res 27 (2004) 143-147
14. Vallance P., Leone A., Calver A., Collier J., and Moncada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol 20 Suppl. 12 (1992) S60-62
15. Cardounel A.J., Cui H., Samouilov A., Johnson W., Kearns P., Tsai A.L., et al. Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial no production and vascular function. J Biol Chem 282 (2007) 879-887
16. Hingorani A.D. Polymorphisms in endothelial nitric oxide synthase and atherogenesis: John french lecture 2000. Atherosclerosis 154 (2001) 521-527
17. Tsikas D., Rode I., Becker T., Nashan B., Klempnauer J., and Frolich J.C. Elevated plasma and urine levels of adma and 15(s)-8-iso-pgf2alpha in end-stage liver disease. Hepatology 38 (2003) 1063-1064
18. Wells S.M., Buford M.C., Migliaccio C.T., and Holian A. Elevated asymmetric dimethylarginine alters lung function and induces collagen deposition in mice. Am J Respir Cell Mol Biol 40 (2009) 179-188
19. Suda O., Tsutsui M., Morishita T., Tasaki H., Ueno S., Nakata S., et al. Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of renin-angiotensin system and oxidative stress. Arterioscler Thromb Vasc Biol 24 (2004) 1682-1688
20. Tsikas D. Analysis of nitrite and nitrate in biological fluids by assays based on the griess reaction: appraisal of the griess reaction in the l-arginine/nitric oxide area of research. J Chromatogr B: Analyt Technol Biomed Life Sci 851 (2007) 51-70
21. Baylis C., and Vallance P. Measurement of nitrite and nitrate levels in plasma and urine-what does this measure tell us about the activity of the endogenous nitric oxide system?. Curr Opin Nephrol Hypertens 7 (1998) 59-62
22. Shaul P.W. Regulation of endothelial nitric oxide synthase: location, location, location. Annu Rev Physiol 64 (2002) 749-774
23. Closs E.I., Basha F.Z., Habermeier A., and Forstermann U. Interference of l-arginine analogues with l-arginine transport mediated by the y+ carrier hcat-2b. Nitric Oxide 1 (1997) 65-73
24. Morris Jr. S.M. Arginine metabolism: boundaries of our knowledge. J Nutr 137 (2007) 1602S-1609S
25. Jacobi J., Sydow K., von Degenfeld G., Zhang Y., Dayoub H., Wang B., et al. Overexpression of dimethylarginine dimethylaminohydrolase reduces tissue asymmetric dimethylarginine levels and enhances angiogenesis. Circulation 111 (2005) 1431-1438
26. Knipp M., Braun O., and Vasak M. Searching for ddah inhibitors: S-nitroso-l-homocysteine is a chemical lead. J Am Chem Soc 127 (2005) 2372-2373
27. Hartzoulakis B., Rossiter S., Gill H., O'Hara B., Steinke E., Gane P.J., et al. Discovery of inhibitors of the pentein superfamily protein dimethylarginine dimethylaminohydrolase (ddah), by virtual screening and hit analysis. Bioorg Med Chem Lett 17 (2007) 3953-3956
28. Rossiter S., Smith C.L., Malaki M., Nandi M., Gill H., Leiper J.M., et al. Selective substrate-based inhibitors of mammalian dimethylarginine dimethylaminohydrolase. J Med Chem 48 (2005) 4670-4678
29. Moroi M., Zhang L., Yasuda T., Virmani R., Gold H.K., Fishman M.C., et al. Interaction of genetic deficiency of endothelial nitric oxide, gender, and pregnancy in vascular response to injury in mice. J Clin Invest 101 (1998) 1225-1232
30. Atzler D., Jacobi J., Strobel J., Cordasic N., Arend M., Schwedhelm E., et al. Effect of enhanced monomethylarginine metabolism by human dimethylarginine dimethylaminohydrolase 1 on plaque formation in apoe-deficient mice. Naunyn-Schmiedeberg's Arch Pharmacol 379 (2009) 97
31. Tokuo H., Yunoue S., Feng L., Kimoto M., Tsuji H., Ono T., et al. Phosphorylation of neurofibromin by camp-dependent protein kinase is regulated via a cellular association of n(g),n(g)-dimethylarginine dimethylaminohydrolase. FEBS Lett 494 (2001) 48-53
32. Hasegawa K., Wakino S., Tanaka T., Kimoto M., Tatematsu S., Kanda T., et al. Dimethylarginine dimethylaminohydrolase 2 increases vascular endothelial growth factor expression through sp1 transcription factor in endothelial cells. Arterioscler Thromb Vasc Biol 26 (2006) 1488-1494
33. Dayoub H., Rodionov R.N., Lynch C., Cooke J.P., Arning E., Bottiglieri T., et al. Overexpression of dimethylarginine dimethylaminohydrolase inhibits asymmetric dimethylarginine-induced endothelial dysfunction in the cerebral circulation. Stroke 39 (2008) 180-184
34. Tanaka M., Sydow K., Gunawan F., Jacobi J., Tsao P.S., Robbins R.C., et al. Dimethylarginine dimethylaminohydrolase overexpression suppresses graft coronary artery disease. Circulation 112 (2005) 1549-1556
35. Konishi H., Sydow K., and Cooke J.P. Dimethylarginine dimethylaminohydrolase promotes endothelial repair after vascular injury. J Am Coll Cardiol 49 (2007) 1099-1105
36. Wang D., Gill P.S., Chabrashvili T., Onozato M.L., Raggio J., Mendonca M., et al. Isoform-specific regulation by n(g),n(g)-dimethylarginine dimethylaminohydrolase of rat serum asymmetric dimethylarginine and vascular endothelium-derived relaxing factor/no. Circ Res 101 (2007) 627-635
37. Valkonen V.P., Tuomainen T.P., and Laaksonen R. Ddah gene and cardiovascular risk. Vasc Med 10 Suppl. 1 (2005) S45-48
38. Akbar F., Heinonen S., Pirskanen M., Uimari P., Tuomainen T.P., and Salonen J.T. Haplotypic association of ddah1 with susceptibility to pre-eclampsia. Mol Hum Reprod 11 (2005) 73-77
39. Kim Y.J., Park B.H., Park H., Jung S.C., Pang M.G., Ryu H.M., et al. No association of the genetic polymorphisms of endothelial nitric oxide synthase, dimethylarginine dimethylaminohydrolase, and vascular endothelial growth factor with preeclampsia in Korean populations. Twin Res Hum Genet 11 (2008) 77-83
40. Jones L.C., Tran C.T., Leiper J.M., Hingorani A.D., and Vallance P. Common genetic variation in a basal promoter element alters ddah2 expression in endothelial cells. Biochem Biophys Res Commun 310 (2003) 836-843
41. Ryan R., Thornton J., Duggan E., McGovern E., O'Dwyer M.J., Ryan A.W., et al. Gene polymorphism and requirement for vasopressor infusion after cardiac surgery. Ann Thorac Surg 82 (2006) 895-901
42. O'Dwyer M.J., Dempsey F., Crowley V., Kelleher D.P., McManus R., and Ryan T. Septic shock is correlated with asymmetrical dimethyl arginine levels, which may be influenced by a polymorphism in the dimethylarginine dimethylaminohydrolase ii gene: a prospective observational study. Crit Care 10 (2006) R139
43. Bai Y., Chen J., Sun K., Xin Y., Liu J., and Hui R. Common genetic variation in ddah2 is associated with intracerebral hemorrhage in Chinese population: a multicenter case-control study in china. Clin Sci (Lond) (2009)
44. Casas J.P., Bautista L.E., Humphries S.E., and Hingorani A.D. Endothelial nitric oxide synthase genotype and ischemic heart disease: meta-analysis of 26 studies involving 23028 subjects. Circulation 109 (2004) 1359-1365
45. Wells S.M., Buford M.C., Migliaccio C.T., and Holian A. Elevated asymmetric dimethylarginine alters lung function and induces collagen deposition in mice. Am J Respir Cell Mol Biol (2008)
46. Morishita T., Tsutsui M., Shimokawa H., Sabanai K., Tasaki H., Suda O., et al. Nephrogenic diabetes insipidus in mice lacking all nitric oxide synthase isoforms. Proc Natl Acad Sci USA 102 (2005) 10616-10621
47. Sydow K., Mondon C.E., Schrader J., Konishi H., and Cooke J.P. Dimethylarginine dimethylaminohydrolase overexpression enhances insulin sensitivity. Arterioscler Thromb Vasc Biol 28 (2008) 692-697
48. Jacobi J., Maas R., Arend M., Atzler D., Böger R.H., and Hilgers K.F. Ddah1 overexpression suppresses plaque formation in apoe-deficient mice by lowering adma levels. Circulation 118 (2008) S366-S367
49. Suvorava T., and Kojda G. Reactive oxygen species as cardiovascular mediators: lessons from endothelial-specific protein overexpression mouse models. Biochim Biophys Acta (2009)